GlassScriptPhysician profile
Shailesh Satpute
NPI 1538460225
$18,563.03
in general payments reported to CMS, 2019-2025
73 companies · $6,745 in 2025
The $6,745 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,928 · 2020: $1,721 · 2021: $585 · 2022: $2,720 · 2023: $2,496 · 2024: $1,367 · 2025: $6,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,154 · Honoraria: $5,040 · Education: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,154.28 |
| Honoraria | $5,040.00 |
| Education | $414.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $5,040.00 | 2025 | |
| Exelixis INC. | $1,256.24 | 2019-2023 | Cabometyx |
| Janssen Biotech, INC. | $862.11 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $736.15 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Novartis Pharmaceuticals Corporation | $703.44 | 2019-2025 | |
| Pfizer INC. | $669.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $562.23 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $553.39 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Seagen INC. | $543.45 | 2019-2025 | Adcetris, Padcev |
| E.R. Squibb & Sons, L.L.C. | $523.50 | 2019-2025 | Opdualag, Opdivo |
| Eisai INC. | $490.51 | 2019-2025 | |
| Incyte Corporation | $479.24 | 2019-2025 | Monjuvi, Pemazyre, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $419.92 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Genentech USA, INC. | $418.03 | 2019-2024 | Lunsumio, Polivy, Phesgo |
| Amgen INC. | $407.25 | 2019-2023 | Xgeva, Nplate, Vectibix |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailesh Satpute listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.